Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Smoking Cessation, Alcohol Drinking
Interventions: Chantix, Behavioral Counseling Sessions, NicodermCQ, Placebo; Drug · Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Skin Infections, Bacterial
Interventions: Retpamulin Ointment, 1%, Linezolid; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 2 Months and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 53
States / cities: Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more

Conditions: Delirium, Impaired Cognition
Interventions: Simultaneous Cycle/Cognitive Training; Behavioral
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 45 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Breast Cancer, Ovarian Cancer, Uterine Cancer, Pancreatic Cancer
Interventions: Hemp-based CBD, Placebo oral tablet; Drug · Other
Lead sponsor: Main Line Health; Other
Eligibility: 21 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Wynnewood, Pennsylvania

Conditions: Depression and Burden in Caregivers
Interventions: Mindoula, DANA; Behavioral · Device
Lead sponsor: AnthroTronix, Inc.; Industry
Eligibility: 45 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Leiomyoma
Interventions: BAY1002670, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 36
States / cities: Mesa, Arizona • Tucson, Arizona • San Diego, California + 29 more

Conditions: Lymphoproliferative Disorder
Interventions: rituximab, cyclophosphamide, methylprednisolone, prednisone; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Heart Failure
Interventions: Empagliflozin 10 mg Tab, Placebo Oral Tablet; Drug
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 19 Years to 119 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 10
States / cities: Los Angeles, California • Jacksonville, Florida • Evanston, Illinois + 7 more

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Enoxaparin + Placebo, Apixaban + Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 3,608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 25
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 17 more

Conditions: Atrial Fibrillation
Interventions: Dronedarone, Placebo (for Dronedarone); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 92
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 79 more

Conditions: Aspirin-Associated Gastric Ulcers
Interventions: PA32540; Drug
Lead sponsor: POZEN; Industry
Eligibility: 55 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Breast Cancer
Interventions: Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 39
States / cities: Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more

Conditions: Parkinson Disease, Constipation
Interventions: Active Investigational Treatment ENT-01; Drug
Lead sponsor: Enterin Inc.; Industry
Eligibility: 30 Years to 90 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 18
States / cities: Fountain Valley, California • Pasadena, California • Englewood, Colorado + 15 more

Conditions: Postpartum Smoking Relapse
Interventions: Bupropion Extended Release Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Prostatic Neoplasms
Interventions: Docetaxel, Leuprolide, Bicalutamide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Healthy
Interventions: PF-07328948, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cystic Fibrosis
Interventions: VX-661 plus ivacaftor combination, Ivacaftor, Placebo (matched to VX-661 plus ivacaftor combination), Placebo (matched to ivacaftor); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more

Conditions: Oral Health
Interventions: ProBiora3 mints, Placebo tablet; Other
Lead sponsor: Oragenics, Inc.; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Breast Cancer
Interventions: Fulvestrant, Everolimus, Placebo; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 25
States / cities: Greenbrae, California • Stanford, California • Rockford, Illinois + 21 more

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, Placebo, Golimumab, methotrexate (MTX), Folic/folinic acid; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Freehold, New Jersey • New York, New York • Jackson, Tennessee + 1 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL/VOX, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL, SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 50
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 35 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Cabozantinib (XL184); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Search by objective public record fields.

Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

Simultaneous Recumbent Cycling and Cognitive Training

Effect of Hemp-CBD on Patients With CIPN

Health-eBrain Study

Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap

Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers

Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers

Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy Subjects

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety "Roll-over" Study (Rollover)

Bupropion for the Prevention of Postpartum Smoking Relapse

A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3)

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma